DRTG(SH:600329) Guohai Securities·2025-08-18 06:43Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1][4]. Core Insights - The company's core product revenue shows steady growth, with self-operated profit growth outpacing industrial revenue. In the first half of 2025, the company achieved operating revenue of 2.651 billion yuan, with industrial main revenue growing by 0.87% year-on-year. Sales of its key product, the "Suxiao Jiuxin Wan," reached 1.128 billion yuan, up 5.45% year-on-year, while "Qingyan Diban" sales surged by 52.28% to 289 million yuan [3][4]. - The company is actively enhancing brand promotion and expanding new retail channels. Initiatives include public welfare actions for "Suxiao Jiuxin Wan" and various promotional activities for other products, leveraging a B2C and O2O dual-driven growth strategy [3][4]. - The medical division is advancing consensus guidelines to promote hospital terminal development, with significant training and development efforts for key products in the cardiovascular and urological fields [3][4]. Financial Performance Summary - For the first half of 2025, the company reported a net profit attributable to shareholders of 1.928 billion yuan, a year-on-year increase of 193.08%, primarily due to a tax-adjusted net gain of 1.308 billion yuan from the transfer of equity in a joint venture [3][4]. - The report forecasts revenue for 2025-2027 to be 4.966 billion, 5.776 billion, and 6.770 billion yuan, respectively, with net profits of 2.169 billion, 1.012 billion, and 1.271 billion yuan, respectively. The corresponding price-to-earnings ratios are projected to be 16, 34, and 27 times [3][5].